What is REBLOZYL® (luspatercept-aamt)?
REBLOZYL is a prescription medicine used to treat anemia (low red blood cells) in adults with:
- beta thalassemia who need regular red blood cell (RBC) transfusions.
- myelodysplastic syndromes who may need regular RBC transfusions and have never received an erythropoiesis-stimulating agent (ESA).
- myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need 2 or more RBC units over 8 weeks and have not responded well to an erythropoiesis-stimulating agent (ESA).
REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia. It is not known if REBLOZYL is safe or effective in children.
Pricing Information
Like many patients, knowing what you may pay for treatment can be a major concern. That’s why Bristol Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP) costs and possible resources that may help make them more affordable.
Click below to learn more about your medication cost based on your injection schedule and insurance coverage.
-
The list price of REBLOZYL is $12,097.42 per injection when given as 75 mg every 3 weeks.* Most patients will pay less.†
*This price does not include the cost of administration or infusion center costs. This list price is current as of Jan 1, 2025.
†WAC is the price at which pharmaceutical manufacturers sell their products to wholesalers. WAC does not take into account discounts that may be available to insurers or other intermediaries, nor does it reflect the value of patient assistance programs or copay support programs. Most people do not pay the list price for REBLOZYL. For adults with beta thalassemia prescribed REBLOZYL for anemia, the starting dose is 1 mg/kg every 3 weeks. Assuming patient weight of
-
If you have commercial insurance
You could pay as little as $0 per injection with the BMS Co-Pay Assistance Program. Learn about this program.
-
If you have Medicare
You could pay $0-$2,399 per injection* if you are receiving REBLOZYL (depending on your specific Medicare benefits). The OOP cost for 75% of injections is $0. If you have Medicare Part B, you may also have a supplemental insurance plan that will pay all or part of your REBLOZYL costs. If you have Medicare Part C, there is an out-of-pocket maximum and what you will pay for REBLOZYL depends on your plan’s benefit design and the level of other healthcare expenses you have during the year. Please check with your Medicare plan administrator for further details.
*Based on the 75th percentile of OOP costs for Medicare patients. Medicare patients could pay $0-2,399 per injection. This price does not include the cost of administration or infusion center costs. -
If you have Medicaid
You could pay $0-$20 per injection (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
-
If you do not have insurance coverage
If you do not have medical coverage for REBLOZYL, you can expect to pay the list price shown above. Patients without insurance are encouraged to call 1-800-861-00481-800-861-0048 to explore potential options.
-
For additional information, the BMS Access Support® Program provides resources to help patients understand their insurance coverage and find information on sources of financial support.
The BMS Co-Pay Assistance program may help eligible commercially insured patients pay $0 per injection. BMS will cover the rest of the cost, up to $10,000 per year per product.
Please visit BMS Access Support or call 1-800-861-00481-800-861-0048, 8AM–8PM ET,
Monday–Friday .
The list price of REBLOZYL is $16,129.91 per injection when given as 100 mg every 3 weeks.* Most patients will pay less.†
*This price does not include the cost of administration or infusion center costs. This list price is current as of Jan 1, 2025.
†WAC is the price at which pharmaceutical manufacturers sell their products to wholesalers. WAC does not take into account discounts that may be available to insurers or other intermediaries, nor does it reflect the value of patient assistance programs or copay support programs. Most people do not pay the list price for REBLOZYL. For adults with myelodysplastic syndromes with ring sideroblasts (MDS-RS) prescribed REBLOZYL for anemia, the starting dose is 1 mg/kg every 3 weeks. Assuming patient weight of
-
If you have commercial insurance
You could pay as little as $0 per injection with the BMS Co-Pay Assistance Program. Learn about this program.
-
If you have Medicare
You could pay $0-$2,399 per injection* if you are receiving REBLOZYL (depending on your specific Medicare benefits). The OOP cost for 75% of injections is $0. If you have Medicare Part B, you may also have a supplemental insurance plan that will pay all or part of your REBLOZYL costs. If you have Medicare Part C, there is an out-of-pocket maximum and what you will pay for REBLOZYL depends on your plan’s benefit design and the level of other healthcare expenses you have during the year. Please check with your Medicare plan administrator for further details.
*Based on the 75th percentile of OOP costs for Medicare patients. Medicare patients could pay $0-2,399 per injection. This price does not include the cost of administration or infusion center costs. -
If you have Medicaid
You could pay $0-$20 per injection (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
-
If you do not have insurance coverage
If you do not have medical coverage for REBLOZYL, you can expect to pay the list price shown above. Patients without insurance are encouraged to call 1-800-861-00481-800-861-0048 to explore potential options.
-
For additional information, the BMS Access Support® Program provides resources to help patients understand their insurance coverage and find information on sources of financial support.
The BMS Co-Pay Assistance program may help eligible commercially insured patients pay $0 per injection. BMS will cover the rest of the cost, up to $10,000 per year per product.
Please visit BMS Access Support or call 1-800-861-00481-800-861-0048, 8AM–8PM ET,
Monday–Friday .
IMPORTANT SAFETY INFORMATION
- have or have had blood clots
- take hormone replacement therapy or birth control pills (oral contraceptives)
- have had your spleen removed (splenectomy)
- smoke
- have or have had high blood pressure (hypertension)
- have a history of extramedullary hematopoietic (EMH) masses
- have or have had enlarged spleen or liver
- are pregnant or plan to become pregnant. REBLOZYL may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with REBLOZYL.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
WHAT ARE THE POSSIBLE SIDE EFFECTS OF REBLOZYL?
REBLOZYL may cause serious side effects, including:
- Blood clots. Blood clots in the arteries, veins, brain, and lungs have happened in people with beta thalassemia during treatment with REBLOZYL. The risk of blood clots may be higher in people who have had their spleen removed or who take hormone replacement therapy or birth control (oral contraceptives). Call your healthcare provider or get medical help right away if you have any of these symptoms:
- chest pain
- trouble breathing or shortness of breath
- pain in your leg, with or without swelling
- a cold or pale arm or leg
- sudden numbness or weakness that are both short-term or continue to happen over a long period of time, especially on one side of the body
- severe headache or confusion
- sudden problems with vision, speech, or balance (such as trouble speaking, difficulty walking, or dizziness)
- High blood pressure. REBLOZYL may cause an increase in your blood pressure. Your healthcare provider will check your blood pressure before you receive your REBLOZYL dose. Your healthcare provider may prescribe you medicine to treat high blood pressure or increase the dose of medicine you already take to treat high blood pressure, if you develop high blood pressure during treatment with REBLOZYL.
- Extramedullary Hematopoietic (EMH) Masses. EMH masses have happened in people with beta thalassemia during treatment with REBLOZYL. You may have a higher risk for developing EMH masses if you have a history of EMH masses, have had your spleen removed, have or have had enlarged spleen or liver, or have low hemoglobin levels. Your healthcare provider will monitor you before you start and during treatment with REBLOZYL. Call your healthcare provider or get medical help right away if you get any of these symptoms:
- severe pain in the back
- numbness or weakness or loss of voluntary movement in feet, legs, hands or arms
- loss of bowel and bladder control
The most common side effects of REBLOZYL include:
- tiredness
- headache
- back, joint, muscle or bone pain
- joint pain
- dizziness
- nausea
- diarrhea
- cough
- stomach (abdominal) pain
- trouble breathing
- swelling of your hands, legs, or feet
- high blood pressure
- allergic reactions
REBLOZYL may cause fertility problems in females. This could affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of REBLOZYL. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
WHAT IS
REBLOZYL is a prescription medicine used to treat anemia (low red blood cells) in adults with:
- beta thalassemia who need regular red blood cell (RBC) transfusions.
- myelodysplastic syndromes who may need regular RBC transfusions and have never received an erythropoiesis-stimulating agent (ESA).
- myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need 2 or more RBC units over 8 weeks and have not responded well to an erythropoiesis-stimulating agent (ESA).
REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia. It is not known if REBLOZYL is safe or effective in children.
Please see full Prescribing Information and Patient Information for REBLOZYL.
You are now leaving this Bristol Myers Squibb site. You are being redirected to another Bristol Myers Squibb site.
Would you like to leave this site?
You are now leaving this Bristol Myers Squibb site
This internet site may provide links or references to other sites. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Would you like to leave this site?